Obagi Medical Products News

A year has passed since I wrote about the trials and tribulations of Obagi Medical Products and the effect they were having on its stock price.

Shares of Obagi Medical Products rose 4.69% on Monday to $12.95 +0.58 and traded as high as $13.15 after being mentioned as a possible acquisition candidate for the second time in as many weeks.

After recently announcing that their Q1 2012 sales rose 16% to a record $30.8 million and notching the highest sales quarter in their firm's history, this specialty pharmaceutical company that develops, markets and sells proprietary skin care systems is rumored to be getting attention from some of the leading consumer cosmetic firms in the world.

The firm currently has a "buy" rating on the stock. Separately, analysts at Canaccord Genuity reiterated a "buy" rating on shares of Obagi Medical Products in a research note to investors on Friday, March 9th.